BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 27022975)

  • 21. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
    Swetzig WM; Wang J; Das GM
    Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M; Barcherini V; Lopes EA; Santos MMM
    Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDMX: from bench to bedside.
    Marine JC; Dyer MA; Jochemsen AG
    J Cell Sci; 2007 Feb; 120(Pt 3):371-8. PubMed ID: 17251377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
    Wang X; Wang J; Jiang X
    J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
    EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL; Cobrinik D
    Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain.
    Ilic VK; Egorova O; Tsang E; Gatto M; Wen Y; Zhao Y; Sheng Y
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The roles and regulation of MDM2 and MDMX: it is not just about p53.
    Klein AM; de Queiroz RM; Venkatesh D; Prives C
    Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
    de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
    J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
    Wasylishen AR; Lozano G
    Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
    Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mdm2 and MdmX: Partners in p53 Destruction.
    Manfredi JJ
    Cancer Res; 2021 Apr; 81(7):1633-1634. PubMed ID: 34003788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.